IONS Reports $246M Q1 Rev, $118M Op Loss, Raises >$3B Oleza Sales Guidance, FDA Accepts sNDA, Zilganersen NDA Reviewed
Ionis Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $75.38
+1.2% in 7d after detection
Post-detection moves
1h
—
1d
-0.1%
3d
+0.8%
7d
+1.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS